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We evaluated the cognitive status of visually impaired patients referred to low vision rehabilitation (LVR) based on a
standard cognitive battery and a new evaluation tool, named the COGEVIS, which can be used to assess patients with
severe visual deficits. We studied patients aged 60 and above, referred to the LVR Hospital in Paris. Neurological and
cognitive evaluations were performed in an expert memory center. Thirty-eight individuals, 17 women and 21 men with
a mean age of 70.3± 1.3 years and a mean visual acuity of 0.12± 0.02, were recruited over a one-year period. Sixty-three
percent of participants had normal cognitive status. Cognitive impairment was diagnosed in 37.5% of participants. The
COGEVIS score cutoff point to screen for cognitive impairment was 24 (maximum score of 30) with a sensitivity of 66.7% and
a specificity of 95%. Evaluation following 4 months of visual rehabilitation showed an improvement of Instrumental Activities of
Daily Living (p = 0 004), National Eye Institute Visual Functioning Questionnaire (p = 0 035), and Montgomery–Åsberg
Depression Rating Scale (p = 0 037). This study introduces a new short test to screen for cognitive impairment in visually
impaired patients.
1. Introduction
Visual impairment, defined as visual acuity of 20/40 or less in
the best-corrected better-seeing eye, affects over 280 million
people worldwide. Excluding curable etiology such as
cataracts or refractive disorders, the most frequent causes
are age-related, such as macular degeneration, glaucoma,
and diabetic retinopathy [1]. The condition of low vision is
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therefore strongly age-dependent and affects more than 73%
of individuals aged over 65 years [2].
Loss of visual acuity impairs many activities of daily
living, including reading, cooking, or selecting clothing/
dressing. Associated loss of the peripheral visual field may
also cause difficulties for detecting obstacles while walking.
Low vision rehabilitation (LVR) delivers multidisciplinary
training including visual strategies, occupational therapy,
and mobility techniques. Optic aids and nonoptic aids such
as tactile marking and signature guides can be used [3]. As
the effectiveness of such a multidisciplinary training is diffi-
cult to evaluate, few studies have been published on the sub-
ject. One study reported a mild improvement of quality of life
after LVR [4].
Even though cognitive and visual impairments are both
frequent in the elderly, the relationship between the two dis-
orders is still a matter of debate. Several studies have reported
an increased cognitive impairment in patients with age-
related macular degeneration compared to age-matched
subjects [5, 6]. In geriatric health services, the percentage of
patients with poor visual acuity was extremely high but
patients with visual impairment were found to have lower
cognitive scores compared to patients with normal vision
[7]. In a large cohort study, the presence of dementia at the
time of diagnosis of age-related macular degeneration is not
different from what is expected by chance at that age [8].
Moreover, studies assessing the association between demen-
tia and visual impairment are limited due to the fact that
many cognitive tests rely on visual skills. Patients presenting
a severe loss of vision or blindness can therefore only com-
plete part of the evaluation.
The main objective of this study was the validation of a
new scale named the COGEVIS to evaluate the cognitive sta-
tus of visually impaired patients and therefore detect mild
cognitive impairment. The COGEVIS evaluates cognitive
function without the use of vision. Our secondary objective
was to determine whether LVR was effective in improving
quality of life and autonomy among elderly patients with
visual impairment.
2. Materials and Methods
2.1. Patients. We performed a monocentric/single-site pro-
spective study including adults aged 60 and above, referred
to the LVR of “Sainte Marie Hospital” of Paris between April
2015 and April 2016. All patients were referred by an
ophthalmologist to the LVR outpatient department after
diagnosis. Exclusion criteria were (1) previously established
diagnosis of neurodegenerative disorder and dementia, (2)
ongoing treatment for cancer or other medical illness that
would preclude participation, (3) severe psychiatric disorder,
and (4) visual acuity of the best eye above 20/70. The study
was approved by the French National Research Ethics Com-
mittee (CPP, Comité de Protection des Personnes dans la
Recherche Biomédicale).
2.2. Evaluation and Care in the Low Vision Rehabilitation
Department. At the initial patient appointment, a detailed
ophthalmologic examination was performed, including
visual acuity, monocular manual visual field, and binocular
manual visual field. Evaluation of autonomy in the daily
living was assessed by a neuropsychologist using Lawton’s
Instrumental Activities of Daily Living (IADL) [9] The
National Eye Institute Visual Functioning Questionnaire
(NEI VFQ 25) was used to assess vision-related health
status [10]. Depressive symptoms were evaluated with the
Montgomery–Åsberg Depression Rating Scale (MADRS)
[11]. Cognitive status was evaluated with the COGEVIS
(COGnitive Evaluation in VISual impairment), a new scale
developed to accommodate impaired vision.
After the first visit, patients followed the low vision reha-
bilitation program. This consisted of multidisciplinary train-
ing performed by optometrists, orthoptists, orientation and
mobility instructors, occupational therapists, physiothera-
pists, and psychologists. Over four months, all patients
attended twice-weekly rehabilitation sessions of three hours
each. Two hours per week, orthoptists and optometrists
worked on improving visual strategies and adjusting devices.
Visual strategies were adapted to a patient’s functional vision.
For example, patients with a central scotoma were trained to
use an eccentric fixation, while patients with a constricted
visual field were taught how to perform visual scanning.
The usefulness of optical devices was also tested: for example,
magnifiers were adapted to the smallest readable character
size and filters for glare control and lamps were proposed.
One hour per week, occupational therapists trained patients
to improve their autonomy in activities of daily living. The
main domains were cooking, personal care, gesture recogni-
tion, self-administrated medication, shopping, and financial
management. Communication instructors taught patients
about computer use for one hour per week. Equipment was
adjusted to each patient’s vision, such as large print
keyboards, magnification software, audio-screen readers, or
text-to-speech converters. Orientation and mobility instruc-
tors trained patients twice a week to improve walking and
mobility autonomy. This work first focused on posture, bal-
ance, and foot placement. Depending on the patient’s func-
tional vision, training for use of long canes or white canes
was proposed, as well as street crossing and public transport
autonomy. Psychologists interviewed patients at the begin-
ning of the program and followed patients twice per month
throughout the rehabilitation period.
At the end of rehabilitation, the evaluation battery was
again carried out, including the IADL, NEI VFQ 25, MADRS,
and COGEVIS scales.
2.3. COGEVIS Description. COGEVIS (COGnitive Evalua-
tion in VISual impairment) is an assessment measure of
cognitive disorders that has the particularity of not solicit-
ing patients’ visual abilities. It has been designed to be
easily applied in everyday practice by various professionals
working with visually impaired patients (e.g., orthoptists
and medical doctors).
It is largely composed of subtests derived from global
efficiency scales: the Mini Mental State Examination
(MMSE) [12], the Frontal Assessment Battery (FAB) [13],
and a brief evaluation battery of gestural praxis [14], which
were adapted to avoid visual modality.
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COGEVIS is composed of
(i) a subtest of memory (learning and (delayed) recall
of 3 words from the MMSE),
(ii) an evaluation of temporospatial orientation
(adapted from MMSE),
(iii) a short computation test (adapted from MMSE),
(iv) an evaluation of language:
(a) denomination based on definitions,
(b) language comprehension (3 orders of the MMSE),
(v) an evaluation of the executive functioning:
(a) letter S fluency in 1min (from the FAB),
(b) similarities (from the FAB),
(vi) an evaluation of the ideomotor apraxia (Mahieux
battery) [14],
(vii) a tactile recognition (naming) test.
COGEVIS is thus a comprehensive cognitive evalua-
tion tool that does not rely on the visual ability to be per-
formed. The scale has a score range of 0–30, with higher
scores indicating better function.
The exact French version of COGEVIS (with the verbal
instructions and quotation system) and an English transla-
tion of it are provided in Supplementary file number 1.
2.4. Cognitive Status Categorization at the Institute of
Memory and Alzheimer’s Disease. Between the initial
appointment and the end of the first month of rehabilitation,
patients were evaluated at the Institute of Memory and
Alzheimer’s Disease (IM2A) of the Pitié-Salpêtrière Hospital
in Paris. Evaluation included a battery of neuropsychological
tests and a consultation with a senior consultant neurologist
specializing in cognitive disorder. The neuropsychological
battery involved only tests that could be performed by
individuals with a visual deficiency, that is, relying more on
auditory-verbal skills than on vision. The assessment was
composed of the MMSE, the FAB, the digit span forward
and backward, lexical (words starting with P) and categorical
(animal names) verbal fluencies, the free and cued selective
memory test, analysis of praxis, and the California Verbal
Learning Test [15]. At the end of the neuropsychological tests
and neurological consultation, a consensual diagnosis was
made to determine (1) if the participant had normal cogni-
tion, mild cognitive impairment (MCI [16]), or a major
neurocognitive disorder based on the DSM-V and (2) in the
case of cognitive impairment, what was the most probable
underlying cause for it. Depending on test results, a MRI
and/or positron emission topography (PET) was proposed
to help confirm diagnosis.
2.5. Statistics. Statistical analysis was performed using the
StatView System. Descriptive statistics are presented with
mean and standard deviation (SD). A comparison of the par-
ticipants with normal cognition (on the basis of a consensual
clinic-neuropsychological evaluation at IM2A) with those
with cognitive impairment (MCI + major cognitive disorder)
was performed using Student’s t-test for continuous variables
after visually ensuring Gaussian distribution or chi-squared
test for binary or categorical variables. Also, we evaluated
the performance of the COGEVIS to diagnose cognitive
impairment in the studied population by examining the
receiver operating characteristic (ROC) curves of this test.
The Wilcoxon signed-rank test was performed to compare
the evolution of the COGEVIS, MADRS, IADL, and NEI
VFQ 25 pre- and postrehabilitation. The level of significance
in all analyses was set at p < 0 05.
3. Results
Thirty-eight subjects from the LVR of Sainte Marie Hospital
of Paris were included in the study. Thirty-two participants
completed a neurological evaluation at the IM2A, and 24
completed the follow-up evaluation after LVR. Their mean
(±standard error of the mean (SEM)) age was 70.3± 1.3
years. The cohort included 17 (44.7%) women and 21
(55.3%) men. They had studied for 10.4± 0.8 years and were
predominantly right handed (87%). Their visual and cogni-
tive statuses are described in Figure 1. A detailed description
of the population including a comparison of the participants
with normal cognition with the cognitively impaired ones
(MCI + major cognitive disorder) is provided in Table 1. Five
patients assessed presented major cognitive disorders; diag-
noses included one person with a mixed pathology origin
(vascular + AD), 2 with typical AD, and 2 with typical Lewy
body dementia (LBD). Administration of the COGEVIS by a
neuropsychologist was feasible and quick (less than 10
minutes for all subjects with a mean administration time
of 5 minutes in cognitively unimpaired patients). Interest-
ingly, COGEVIS scores were significantly different between
the two groups both at baseline and at follow-up evalua-
tion. In addition, while the cognitively normal participant’s
COGEVIS scores slightly improved between baseline and
follow-up evaluation 4 months later, scores of cognitively
impaired participants slightly decreased.
Using the ROC curve method to assess the value of
COGEVIS to diagnose cognitive impairment results showed
an area under the ROC curve of 0.84. The cutoff point that
maximized sensitivity and specificity was 24 with a sensitivity
of 66.7% and a specificity of 95% (Figure 2).
Finally, among the 24 subjects who completed a follow-
up evaluation after LVR, an improvement of cognition
(COGEVIS), functional ability (IADL), quality of life (NEI
VFQ 25), and depressive symptoms was observed after 4
months of LVR as displayed in Table 2.
4. Discussion
The present study responds to an unmet need for an appro-
priate diagnostic measure of cognitive impairment in
patients with visual deficiency. We developed a new cognitive
tool, the COGEVIS, based on the combined expertise of cog-
nitive neurologists, neuropsychologists, and LVR specialists.
This new scale is the first comprehensive scale to be validated
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in a cohort of elderly patients with visual deficiency in whom
cognitive impairment is underdiagnosed or wrongly attrib-
uted to visual impairment [17]. In this study, COGEVIS
was able to identify cognitive impairment with a good diag-
nostic value (area under the ROC curve of 0.84) and was also
used to assess cognitive evolution after LVR. Previous studies
screened visually impaired patients with only part of the test
omitting items that require image processing. The Leipzig
Longitudinal Study of the Aged reported results of part of
the MMSE with a maximum total score of 22 instead of 30.
Validity of the results was limited, restricted to individuals
with very high or very low cognitive performance [18].
Although the small number of participants did not allow
for statistical analysis of major neurocognitive disorder etiol-
ogy, we qualitatively note that the frequency of cognitive
impairment in this population was high, compared to the fre-
quency in the general population [19]. We also found that
there was a high percentage of LBD among participants pre-
senting cognitive impairment. Importantly, LBD diagnoses
in our study were made according to the latest McKeith
et al. criteria [20] and not only proposed in the instance of
visual hallucinations. In visual deficiency, there is a high
prevalence of visual hallucination related to Charles Bonnet
syndrome, a condition in which visual hallucinations develop
in association with visual deprivation [21–23]. This condi-
tion does not elicit either Parkinsonism or major cognitive
fluctuations, two of the three major clinical criteria for
LBD. Moreover, we systematically searched for supportive
features such as REM sleep behavior disorder, dysautonomia
(constipation, orthostatic hypotension), or anosmia to
strengthen diagnosis accuracy. However, Charles Bonnet
syndrome may not be a benign disease. In Lapid et al.’s study,
after an average follow-up time of 33 months, 26% of patients
presenting Charles Bonnet syndrome developed dementia.
The most commonly diagnosed form of the dementia was
LBD [24]. Factors associated with Charles Bonnet syndrome
negative outcome were fear-inducing and longer-lasting hal-
lucination episodes associated with a reduction of daily activ-
ities [21]. LBD is a disease in which the primary visual cortex
is often hypometabolic on fluorodeoxyglucose PET studies
[25]. Chronic visual deficiency may induce a vulnerability
of the posterior cortex, favoring the development of Lewy
MCI
22%
NC
63%
Mixed (vascular/AD)
3%
LBD
6%
AD 6%
Major neurocognitive disorder
15%
(a)
Moderate visual
deficiency
37%
Severe visual
deficiency
16%
Corneal dystrophy 3%
Retinal central veinous
occlusion 3%
Glaucoma
32%
Myopia
18%Age related macular degeneration 16%
Blindness 47%
Retinal dystrophy 5%
Optic neuropathy 5%
Diabetes retinopathy
13%
Uveitis
5%
(b)
Figure 1: Distribution of the participants according to cognitive status (a) or visual status (b). AD: Alzheimer’s disease; LBD: Lewy body
dementia; MCI: mild cognitive impairment; NC: normal cognition.
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body dementia. However, this is not substantiated in our
study, as neither the degree nor the duration of visual
deficiency was associated with cognitive performance. Other
factors, which could not be evidenced from this study, could
be assessed in a larger cohort of visual deficiency patients
followed longitudinally.
The evolution in scores between initial and follow-up
assessments after 4 months indicates the efficacy of LVR
to improve visually impaired patients’ functional abilities
and their quality of life. This contributes further evidence
in addition to the few studies published on the improve-
ment of quality of life [4] and ongoing utility of LVR in
treating patients aged 60 and above. Interestingly, LVR
improved cognition according to the significant increase
in COGEVIS scores possibly related to the learning of
new strategies for planning and organization. We could
identify a subgroup of patients with pre-LVR cognitive
impairment who did not benefit from LVR, as their
post-LVR COGEVIS scores were lower than those at base-
line. However, this result does not invalidate LVR in
patients with cognitive impairment. Firstly, the low number
of cognitively impaired participants does not allow us to
draw general conclusions about this result following LVR.
Secondly, a specific study, focused only on LVR efficacy
in this subgroup of patients, should be conducted in a ran-
domized, placebo-controlled, double blind trial in order to
assess the true impact of this therapy. Our study empha-
sizes that knowing the cognitive status of visually impaired
patients before LVR is critical to inform the patient and
his family of possible outcomes and adjust expectations
regarding LVR.
In previous studies, loss of visual acuity has been reported
to be significantly associated with depression [26–28]. Inter-
views of visually impaired patients older than 60 pointed out
the high prevalence of depression in this population (more
than 30%) compared to normally sighted peers [29]. In our
study, MADRS scores used to assess depressive symptoms
showed above average rates of depression among visually
deficient patients and higher rates when visual deficiency
was associated with cognitive impairment. Depressive symp-
toms also decreased after LVR. Therefore, discrimination
between purely depressive syndromes with cognitive com-
plaints and cognitive impairment due to neurodegenerative
diseases is important to adapt the objectives and indication
of LVR. COGEVIS could be a suitable test to separate these
two syndromes.
Table 1: Description of the population comparing participants with normal cognition (NC) to cognitively impaired (CI) ones.
NC (N = 20) CI (N = 12) p value
Age 69.1 (1.7) 75.0 (2.2) 0.04
Gender: female 9 (45) 7 (58.3) 0.5
Years of education 11.8 (1) 7.9 (1.3) 0.02
Right handedness 15 (75) 12 (100) 0.12
MMSE 26.1 (0.8) 20.1 (1) 0.0001
FAB 14.9 (0.6) 10.8 (0.7) 0.0001
Digit span forward 5.8 (0.2) 4.7 (0.3) 0.005
Digit span backward 4.2 (0.2) 3.2 (0.3) 0.03
CVLT total recall score 53.2 (2.4) 33.2 (2.1) 0.0001
Intrusions 0.8 (0.6) 3.1 (0.7) 0.02
Recognition 15.2 (0.5) 12.6 (0.7) 0.008
False recognition 0.6 (0.6) 4.3 (0.8) 0.02
Categorical (animals) fluency 29.0 (2.1) 18 (2.7) 0.004
Lexical (letter P) fluency 21.4 (1.8) 12.8 (2.4) 0.008
WAIS-IV vocabulary 10.7 (0.7) 7.0 (0.8) 0.003
Symbolic praxis 4.9 (0.1) 4.6 (0.2) 0.06
Pantomime praxis 9.8 (0.3) 8.9 (0.3) 0.04
MADRS 13.3 (2.4) 17.5 (3.3) 0.3
Baseline COGEVIS 27.5 (0.6) 22.9 (0.8) 0.0001
Follow-up COGEVIS 28.4 (0.9) 21.7 (1.1) 0.0002
Visual deficiency duration (years) 8.1 (1.9) 7.6 (2.5) 0.9
Best-seeing eye visual acuity 0.13 (0.02) 0.10 (0.03) 0.6
IADL 14.2 (1.2) 20.6 (1.5) 0.002
NEI VFQ 25 35.8 (2.9) 28.4 (3.6) 0.12
Values expressed as mean (SEM) and t-tests performed for continuous variable or N (%) and chi-squared test performed for categorical variables. CVLT:
California Verbal Learning Test; FAB: Frontal Assessment Battery; IADL: Lawton’s Instrumental Activities of Daily Living; MADRS: Montgomery–Åsberg
Depression Rating Scale; MMSE: Mini Mental State Examination; NEI VFQ 25: National Eye Institute Visual Function Questionnaire; WAIS-IV: Wechsler
Adult Intelligence Scale—Fourth Edition.
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5. Conclusion
COGEVIS is a new, simple, and useful test to screen for
cognitive impairment in visually impaired patients. It can
also help in the assessment of therapeutic interventions
(e.g., LVR) in this population.
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7Behavioural Neurology
COGEVIS 
Registration: / 3 
 "I will read you three words. Repeat them and try to hold them back because I will ask for 
them again" 
1. Cigar / 1 
2. Flower / 1 
3. Door / 1 
 
Temporo-spatial orientation: / 5 
"I will ask you some questions about the date of the day and the place where we are." 
1. What is the year?  / 1 
2. What is the month?  / 1 
3. What day of the week?  / 1 
4. What is the name of the hospital / clinic / facility where we are?  / 1 
5. What city are we in?  / 1 
 
Attention and calculation: / 3 
"Count backwards from 100 by removing 7 each time until I stop you. 100-7 ... " 
1. 93 / 1 
2. 86 / 1 
3. 79 / 1 
 
Language: / 8 
"I will ask you a few questions, try to answer as precisely as possible." 
1. What object can give the time? (Accepted: watch, clock, pendulum) / 1 
2. What object is used when it rains? (Accepted: umbrella, boots, raincoat) / 1 
 
"Listen well and do what I am going to tell you" 
3. Take the sheet of paper placed on the table in front of you with your right hand / 1 
4. Fold it in half / 1 
5. And throw it on the ground / 1 
 
Lexical fluency: letter S (in 1 min): 
"Name a maximum of different words starting with the letter S, for example animals, plants 
... but no proper names (first names, names of cities or countries)". 
Quotation details:  3: ≥ 10 words/   2: 6 to 9 words/   1: 3 to 5 words/   0: 2 words or less    / 3 
 
Praxis: / 3 
"How do you do with the hand to do ...". 
1. Military Salute / 1 
2. Send a kiss / 1 
3. Drinking a glass / 1 
 
 
 
 
Touch Recognition: / 2 
"Now you're going to have to recognize objects that I'll put in your hand one by one. What is 
the name of this object? " 
1. Coin / 1 
2. Pen / 1 
 
Recall: / 3 
"Can you recall the words you had to remember earlier? ". 
1. Cigar / 1 
2. Flower / 1 
3. Door / 1 
 
Executive functions: / 3 
Similarities: "how are they alike ..." 
1. A banana and an orange?  / 1 
2. A table and a chair?  / 1 
3. A tulip, a rose and a daisy?  / 1 
  
